We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 110.00 | 105.00 | 115.00 | 110.00 | 110.00 | 110.00 | 600 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -5.03 | 14.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/1/2021 16:09 | archlight That is pretty serious, but pretty good for FDBK. Didn't pick that up. I wonder if that was the reason for buying here... Where's my PinSentry and how much spare cash have I got... | yump | |
09/1/2021 15:53 | QPR 0 Fulham 0 H-T. A prime example of just how boring football can be. Come on U R's. | lr2 | |
09/1/2021 15:49 | “Watch this space” yump. | ducatiman | |
09/1/2021 14:40 | I’m hoping for a steady increase in Bleepa revenue for a year or so and then some signs of acceleration that might indicate a much bigger market. For the time being just a few modest contracts will do - then its £ value is at least proven to a few customers. The problem with the NHS is that nothing seems to adopted at pace and scale, so each sale takes a lot of effort and there’s not much ‘viral’ adoption. Ie. Each trust and each group of clinicians seem to be a law unto themselves. To some extent there is noone in charge. You can’t just convince part of the buying department and then sales go company-wide. | yump | |
09/1/2021 14:19 | OK, so you don't see Feedback as a multibagger. What do you expect from it? | lr2 | |
09/1/2021 13:46 | Oh and by the way I don’t need to be told why I should or shouldn’t be here. I don’t believe in multibaggers based on what I would like to happen in my imagination. If you’ve ever tried to sell great products into the corporate world you wouldn’t get carried away. | yump | |
09/1/2021 13:42 | I’m here for what might be realistic gains. 15% of any market in two years is amazing. 15% of the NHS comms market in 2 years - zero chance. Its the addressable market that matters and that is a fraction of the NHS comms market. | yump | |
09/1/2021 13:14 | Yes, it’s been quiet since RS bought 5m and TO said watch this space. | ducatiman | |
09/1/2021 13:01 | I hope you guys are correct. I still do not like the silence. | brasso3 | |
09/1/2021 12:50 | Worldwide market LR2! | ducatiman | |
09/1/2021 12:20 | You shouldn't be here if you expect Bleepa to only get a small fraction of the NHS communications market Yump. It would be seen as a failure for a product with two unique selling points. I'm assuming the company might get 15% of the possible NHS comms market in the next two years. 15% of £72 mil is £10.8 mil. That should be more than enough to value Feedback as a growth company and rate it as at least £100 mil mcap. £100 mil / 1,067,000 shares would be a share price of 0.937p. That will do for starters. | lr2 | |
09/1/2021 09:49 | The potential markets for new products always look big, but the reality is a smallish % of that market as a target. The addressable market here is only for clinicians who need the functionality, which is a fraction of the total. I don’t know what fraction, but imo feedback, if successful will get a fraction of that fraction. Unless policy takes over, which would be game-changing. | yump | |
09/1/2021 09:40 | Shame the big baggers usually take longer than ARB, otherwise a couple compounded would be a retire early job. | yump | |
09/1/2021 08:46 | ARB I was in TXP at 12p with a lot of shares. Sold mostly between 30p and 60p. That one still haunts me! | brasso3 | |
09/1/2021 08:17 | TXP Brasso? Fingers crossed LR2! I feel a Carlsberg RNS coming. | ducatiman | |
09/1/2021 02:12 | Congrats on the 20 bagger Brasso. Best I've managed was a 17 bagger. I think we can make double figures here Brasso. Check out the below info. NHS England workforce. Consultants - 49,585 Junior Doctors - 57,394 Other Doctors - 11,302 ____________________ Subtotal - 118,281 Nurses and Health Visitors - 298,071 Scientific, therapeutic and technical staff - 147,729 Midwifes - 22,141 Ambulance staff - 16,707 ____________________ Subtotal - 484,648 118,281 + 484,648 = 602,929 doctors, nurses etc in NHS England. Income per annum for Bleepa on 100% take up - 602,929 x £10 per month x 12 months = £72,351,480. No GP's, no dentists, no vets (oh yes) and no armed forces (again oh yes) included in figures. No medical staff for for Ireland, Wales & Scotland included in figures. No overseas sales (India & Arabia for instance) included in figures. Only CE certified product, only clinical quality imaging product. Two very strong USPs. In short not much opposition to Bleepa at this time. Expect sign ups to really take off in next financial year as hospitals have overspent in current financial year (bloody Covid). NHSx should provide some income over next few months I'd hope, though it must be a hard sell to get this into hospitals overwhelmed by Covid. Who has the time to integrate a new comms system in an active hospital environment during a pandemic? Bank a few million in revenue over next few months with more coming in from April onwards would be my hope. Never underestimate that hospitals will already have already signed up for comms packages whether it be pagers, Medic Bleep etc. These on-going agreements will need to end before taking on Bleepa but make no mistake the hospitals will have to do this if they want the security of a CE marked and clinical quality imaging product. These are Bleepa's unique selling points. No other UK, European, Asian company can match them. I might have seen one in the USA but not 100% certain about that yet - it's a private company and full info is very difficult to obtain. When Feedback bring in £10 million revenue a year wouldn't you expect a market capitalisation of something over £100 million? That will put the share price into low double figures and that is only the beginning of what can be achieved here. | lr2 | |
09/1/2021 01:24 | LR2 I have had my first 20 bagger this month. I will take FDBK at double figures (10 bagger) though if that what is on offer! :) | brasso3 | |
08/1/2021 22:56 | A few good Bleepa contracts and I won't be worrying about single figure prices. | lr2 | |
08/1/2021 22:33 | There is the long term resistance level here at 1.35p and a bit of noise to get through at 1.5p. A good RNS should put that to be. | brasso3 | |
08/1/2021 20:06 | Another late trade. I'll leave you to figure out whether it's a buy or sell. 08-Jan-21 16:39:14 1.35p 1,000,000 | lr2 | |
08/1/2021 16:17 | TexRAD Lung perhaps. | lr2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions